Abbonarsi

Multicenter, randomized, controlled trial of confocal laser endomicroscopy assessment of residual metaplasia after mucosal ablation or resection of GI neoplasia in Barrett's esophagus - 15/08/12

Doi : 10.1016/j.gie.2012.05.004 
Michael B. Wallace, MD, MPH 1, , Julia E. Crook, PhD 1, Michael Saunders, MD 2, Laurence Lovat, MD 4, Emmanuel Coron, MD 3, Irving Waxman, MD 5, Prateek Sharma, MD 6, Joo H. Hwang, MD 2, Matthew Banks, MD 4, Mathieu DePreville, MD 3, Jean P. Galmiche, MD 3, Vani Konda, MD 5, Nancy N. Diehl, MD 1, Herbert C. Wolfsen, MD 1
1 Mayo Clinic, Jacksonville, Florida, USA 
2 University of Washington, Seattle, Washington, USA 
3 Nantes University Hospital (CHU) Nantes, Nantes, France 
4 University College London, London, United Kingdom 
5 University of Chicago, Chicago, Illinois, USA 
6 University of Kansas, Lawrence, Kansas, USA 

Reprint requests: Michael B. Wallace, MD, MPH, 4500 San Pablo Road, Jacksonville, FL 32224

Riassunto

Background

Endoscopic ablation is an accepted standard for neoplasia in Barrett's esophagus (BE). Eradication of all glandular mucosa in the distal esophagus cannot be reliably determined at endoscopy.

Objective

To assess if use of probe-based confocal laser endomicroscopy (pCLE) in addition to high-definition white light (HDWL) could aid in determination of residual BE.

Design

Prospective, multicenter, randomized, clinical trial.

Setting

Academic medical centers.

Patients

Patients with Barrett's esophagus undergoing ablation.

Intervention

After an initial attempt at ablation, patients were followed-up either with HDWL endoscopy or HDWL plus pCLE, with treatment of residual metaplasia or neoplasia based on endoscopic findings and pCLE used to avoid overtreatment.

Main Outcome Measurements

The proportion of optimally treated patients, defined as those with residual BE who were treated and had complete ablation plus those without BE who were not treated and had no evidence of disease at follow-up.

Results

The study was halted at the planned interim analysis based on a priori criteria. After enrollment was halted, all patients who had been randomized were followed to study completion. Among the 119 patients with follow-up, there was no difference in the proportion of patients achieving optimal outcomes in the two groups (15/57, 26% for HDWL; 17/62, 27% with HDWL + pCLE). Other outcomes were similar in the two groups.

Limitations

The study was closed after the interim analysis due to low conditional power resulting from lack of difference between groups as well as higher-than-expected residual Barrett's esophagus in both arms.

Conclusion

This study yields no evidence that the addition of pCLE to HDWL imaging for detection of residual Barrett's esophagus or neoplasia can provide improved treatment. (Clinical trial registration number: NCT01032044.)

Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : BE, GM, HDWL, HGD, HGN, IM, LGD, LGN, pCLE, RFA


Mappa


 DISCLOSURE: Mauna Kea Technologies provided funding for this study to M. Wallace as a grant, I. Waxman and V. Konda as honoraria, and P. Sharma as research support. I. Waxman also received consulting fees from Olympus, and P. Sharma received research support from Olympus. No other financial relationships relevant to this publication were disclosed.
 If you would like to chat with an author of this article, you may contact Dr Wallace at Wallace.michael@mayo.edu.


© 2012  American Society for Gastrointestinal Endoscopy. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 76 - N° 3

P. 539 - settembre 2012 Ritorno al numero
Articolo precedente Articolo precedente
  • Longer inspection time is associated with increased detection of high-grade dysplasia and esophageal adenocarcinoma in Barrett's esophagus
  • Neil Gupta, Srinivas Gaddam, Sachin B. Wani, Ajay Bansal, Amit Rastogi, Prateek Sharma
| Articolo seguente Articolo seguente
  • A prospective comparative study of optical coherence tomography and EUS for tumor staging of superficial esophageal squamous cell carcinoma
  • Waku Hatta, Kaname Uno, Tomoyuki Koike, Katsunori Iijima, Naoki Asano, Akira Imatani, Tooru Shimosegawa

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.